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Abstract: The internationalisation of firms is increasingly concerned with 
locating innovation activities in the most appropriate locations, 
particularly for more strategic research and development projects. This 
paper reviews the historical development of AstraZeneca (AZ) in China 
since the 1990s and the recent establishment of one of its key global 
innovation centres in the country. The case confirms a newly emerged 
development in the internationalisation of innovation and knowledge 
sourcing by MNEs from advanced economies to emerging countries – the 
‘South’ originated waves.  A review of previous and recent literature 
reveals the growing trend towards ‘unconventional’ knowledge-seeking 
strategy of MNEs. This paper refines and extends current research on 
global innovation strategy by providing a contextually-rich and analytical 
narrative of a longitudinal case study. We identified and explained a 
historical pattern of evolution of AZ’s operation in China from 
innovation to the country to innovation from the country. This paper 
concludes with recommendations and limitations.  
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1. Introduction  
The internationalisation of firm has been a major topic in international business studies. 
The well-established internationalisation theories (Johanson and Vahlne 1977, Kogut and 
Singh 1988, Xu and Shenkar 2002) argue that multinational enterprises (MNEs) usually 
start expanding in neighbouring countries with similar business systems, or countries with 
similar cultures, then gradually move to some less-advanced economies (Vernon 1966).  
 
 Departing from Vernon’s product cycle (Vernon 1966) where innovation was 
analysed as a centralised activity normally located at the home country of the MNE, 
Ronstadt’s (1977) seminal work provided evidence of a different strategy to innovation i.e., 
that of decentralisation where MNEs, through a network of overseas R&D units, adapted 
and generated existing or new knowledge respectively. By moving innovation to 
strategically important locations which were either geographically-close or contextually-
similar countries, MNEs can have close control over key activities whilst benefiting from 
locational advantages (Porter 1989, Dunning 2000, Johansson and Vahlne 1977, 2009). 
This knowledge sourcing activity is viewed as the ‘North-North’ development. In this 
context the extant literature focuses on the varied roles of R&D units which in turn is 
closely associated with the differentiated roles of MNEs’ subsidiaries (Cantwell and 
Mudambi 2005, Pearce 1999, Ronstadt 1978) resulting in a mixture of Global Innovation 
Strategies (GIS) pursued by MNEs. The core assumption of MNEs’ GIS is evolving 
around a North-North and North-South paradigm where the South, being emerging 
economies, were viewed at best as augmenters of existing MNE knowledge which in turn 
was developed within a North-North nexus of countries (Pearce and Papanastassiou 1997; 
Papanastassiou and Pearce 2009; Jha et al. 2015).  
Challenging the dominance of this traditional paradigm, a rather different 
phenomenon has emerged in recent years, which is the increasingly apparent trend of the 
internationalisation of innovation to dissimilar and distant less-advanced or emerging 
countries (Altenburg et al 2008; Haakonsson and Ujjual 2014; Haour and Jolly 2014). A 
recent World Investment Report (2005) published by United Nations Conference on Trade 
and Development provides statistics which indicate a significant growing number of R&D 
units in emerging economies.  Similarly, McKinsey in its 2011 survey confirms the growth 
of overseas MNE R&D units in emerging economies (McKinsey, 2011). What makes this 
phenomenon intriguing is that a quite large number of these overseas R&D units depart 
from traditional technology adaptation roles and evolve into generators of new knowledge , 
a role that so far has been considered to be restricted to, as discussed above, a handful of 
North i.e., developed economies. This invites debate on whether and how MNEs source 
knowledge from emerging economies, i.e., the South-North trend. Whilst there has been an 
increasing number of research exploring this new trend (e.g. Altenburg et al 2008, Aubert, 
2004, Balachandra 2006, Haakonsson and Ujjual 2014, Haour and Jolly 2014, and Li and 
Yue 2005), yet, detailed research remains scarce to date. 
Hence, the purpose of this paper is to contribute to the understanding of the 
internationalisation of innovation by advance-economy MNEs in emerging economies. 
More specifically, it attempts to take a historical case-study approach to review, describe, 
and analyse the development of innovation activities undertaken by AZ in China over the 
last two decades. Whilst the majority of the advance-economy MNEs have had a long 
tradition of maintaining close control of critical innovation activities by locating in close-
by or similar markets, e.g., economically developed, politically stable, and legally 
protected (Porter 1989, Dunning 2000, Johansson and Vahlne 1977, 2009), the new 
phenomenon and the case of AZ in China strongly ‘contradict’ with the long-established 
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norm. Against this background, the paper aims to address a number of key research 
questions: What is the evolutionary process of AZ’s R&D activities in China? Whether and 
how can existing theories explain the case of AZ in China? What are the practical lessons 
which can be learned from the case of AZ in China for others? In doing so, this paper aims 
to make a number of important and timely contributions. First, it intends to challenge the 
conventional wisdom of innovation internationalisation in existing literature and 
empirically investigate the growing trend of emerging economies in offering knowledge 
sourcing opportunities for MNEs, including those embodied in new products aimed at the 
global markets. Second, this study aims to make an empirical contribution by investigating 
the potential evolutionary pattern of knowledge sourcing in the country by MNEs 
originated from advance-economies. While the waves of internationalisation of innovation, 
which can be modelled as ‘North to North’ (wave 1) and ‘North to South’ (wave 2), have 
been the more accepted developments in existing literature, it is argued that the there has 
been a gradual shift towards ‘South to South’ (wave 3) and ‘South to North’ (wave 4), with 
the fourth one being the most recent (Altenburg et al 2008, Aubert, 2004, Balachandra 
2006, Haakonsson and Ujjual 2014, Haour and Jolly 2014, and Li and Yue 2005). Yes, this 
is still largely under acknowledged and not properly investigated. 
 
2. A Theoretical Review of the Internationalisation of Innovation   
There is a range of theoretical perspectives in interpreting the motivations of 
internationalisation, which so far has reflected three waves of developments. The earliest 
wave was around WWII and thereafter, when sending products and expanding production 
to outside the home country was the first step in internationalisation (Jha et al. 2015). For 
instance, Williams (1985) and Hennart (1988) focus on the behavioural related theories of 
internationalisation’. They draw upon the concept of ‘transaction cost economics’ and 
argue that firms entering foreign markets through certain strategic methods are based on 
the transaction cost level for transferring knowledge to a foreign organization. Similarly, 
Reid (1983) argues firms internationalise their operations in order to minimise costs 
incurred during organizational activities. Reversely, Hymer (1976) and Caves (1982) put 
forward the monopolistic advantage theory where a superior advantage of a firm 
developed in the home country can be transferred overseas at no additional costs due to its 
established knowledge. Moreover, Knickerbocker (1973)’s oligopolistic reaction theory 
suggests that firms imitate each other’s internationalisation actions to reduce the risk of 
being different and causing failure. Lastly, Dunning (1977, 1979) develops his ‘eclectic 
theory’ and suggest that foreign direct investment occurs when the home firm possesses a 
unique set of assets and the host country is relatively advantageous in location. Other 
researchers include Vernon (1966) who argued on the product cycle process, and Johanson 
and Vahlne (1977) who presented their incremental process view – the Uppsala Model – to 
demonstrate that firm internationalisation goes through four key stages as a result of 
accumulated experiential knowledge and increasing commitments: from irregular exports, 
to export via independent agents, to established overseas sales offices, and to building 
overseas manufacturing facilities.   
 Whilst these established theories have strong explanatory power for various aspects 
of the internationalisation phenomenon, and therefore hold high level of recognition in 
international business research, it is fair to conclude that little direct attention or detailed 
explanations have been given to a more recent and strategically-important firm movement, 
i.e., innovation internationalisation. It is also reasonable to argue that those theories have 
not fully captured this development as they advocated that the benefits of keeping strategic 
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innovation at home significantly override the benefits of internationalising innovation 
activities. This view was particularly supported by Porter (1989) who sees innovation as a 
core business unit of a firm, and believes that home-country innovation could bring strong 
international competitive advantages, whereas allocating innovation overseas forgoes such 
a benefit. In support of Porter’s view, a number of scholars (Vernon, 1966, Vahlne and 
Johanson, 1977 and Casson, 1992) generally argue that, while many foreign countries are 
ideal targets for market expansion and/or production, they are viewed as less attractive 
locations for innovation activities due to reasons such as lack of skilled labour for 
sophisticated operations, dissimilar country factors, barriers in information flows, and 
potential loss of management control of strategic activities. Hence, innovation activities 
are kept in close distance (Dunning, 1993). 
 The second wave emerged as the critiques of those established theories came alight 
later when the wider international business environment witnessed significant changes, 
such as the increasing international competition and the rapid advancement in information 
and communication technologies (Yamin and Sinkovics, 2010, Yu 2011). To survive and 
succeed in this ever more challenging and open environment, firms gradually became more 
agile when it came to creating and sustaining competitive advantages as evidenced by the 
emergence of new organisational forms such as heterarchy, hierarchy, and the matrix 
(Bartlett and Ghoshal, 1989, Hobdari, et al 2012).  In particular, industries saw a 
tremendous change since the 1980s which challenged the conventional wisdom of keeping 
strategic development and innovation nearby. It was believed that such a centralised 
approach to innovation was no longer sufficient and appropriate (Kuemmerle, 1997). 
Instead, firms needed to develop global innovation networks that excelled at tapping new 
centres of knowledge and at commercialising products in foreign markets with the speed 
necessary to remain competitive. Consequently, the internationalisation of innovation 
became critical for many advance-economy firms. However, it was not an overnight 
experience. Many researchers found that firms tended to start with exploiting home-based 
knowledge (adaptors) in foreign locations as the first step in the internationalisation of 
innovation. As local subsidiary’s involvement deepened, knowledge exploitation gradually 
advanced to local knowledge generation for the local market based on subsidiary 
experience. Finally, many of these subsidiaries became the ultimate global competence 
creators as their unique R&D capabilities developed overtime (Kuemmerle 1999). At the 
same time, differing national innovation systems provided the ideal multiple learning 
environments for dispersed subsidiaries (Nelson 1993, Porter 1990). Subsequently, 
innovation was seen as a process of leveraging strategic knowledge resources from 
multiple locations and integrating into global products (Gassmann and von Zedtwitz, 1999, 
Granstrand et al, 1993, Kogut and Zander, 1993). Hence, the building and maintenance of 
a sustainable GIS and an effective global innovation network became a top priority for 
knowledge-intensive firms.  
 Moreover, most of these internationalised innovation activities at the time were 
located in developed countries, particularly in USA, Japan, and Europe, and extremely 
limited investments were made in emerging economies such as the BRICS nations 
(Altenburg et al 2008, Aubert, 2004, Balachandra 2006, Haakonsson and Ujjual 2014, 
Haour and Jolly 2014). Academically, research in this tradition paid most attention on the 
magnitude of this phenomenon (Cantwell 1995; Patel and Pavitt 1991), and converged on 
the idea that international knowledge sourcing was a ‘North to North’ phenomenon with 
innovation investments departing from advanced economies and destined to other 
advanced economies (Arvanitis and Hollenstein 2011; Cantwell and Piscitello 2000). 
Therefore, international knowledge sourcing was mainly concerned with locations of 
advanced economies on the basis of knowledge-related advantages (Dunning and Narula 
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1995; Florida 1997; Pearce and Papanastassiou 1999). In contrast, a consensus among 
these researchers is that emerging economies were characterised by low innovativeness 
and therefore were least interested by MNEs when internationalising strategic innovation. 
 However, a number of most recent studies  reveal a rather different picture where a 
growing proportion of the investment from firms of developed economies has been 
devoted to innovation-related activities in a number of emerging economies, particularly 
Asia, indicating a ‘North to South’ trend (Altenburg et al 2008; Balachandra 2006; Li and 
Yue 2005). Moreover, pictures of ‘South to South’ and ‘South to North’ are painted by 
increasing number of studies (Contractor et al. 2010; D'Agostino et al. 2013; Hadengue et 
al 2015; Haakonsson and Ujjual 2015). Both ‘South to South’ and ‘South to North’ 
phenomena upgrade our view on the internationalisation of innovation as per extant 
literature. This evidence demonstrates that emerging countries are no longer viewed by 
firms from developed economies as only targets for market expansions and production, but 
also increasingly important locations for knowledge sourcing. Thus, the emergence of 
‘non-traditional’ locations has pushed innovation internationalisation to a truly global 
phenomenon. A study by Hadengue et al (2015) discusses the reverse innovation and 
knowledge transfer from China to the rest of the world. Similarly, Altenburg et al (2008) 
and Haakonsoon and Ujjul (2014)  argue that emerging countries such as India and China 
are quickly becoming the latest attractive destinations for R&D investments as the 
countries have been going under national transitions from a hotspot of production to 
innovation. 
 In spite of this recent development in international business and limited recent 
studies, there is fairly scarce research so far in attempting to explain the development of 
innovation internationalisation to emerging economies (Li and Kozhikode 2009; Mahmood 
and Zheng 2009; Tsai, et al. 2009; Fu, et al. 2011; McMahon and Thorsteinsdóttir 2013; 
Qu, et al, 2013; Ponomariov and Toivanen 2014; Kafouros, et al 2015; Watkins, et al 
2015). This paper extends the traditional view of ‘North to North’ and ‘North to South’ 
styles of innovation internationalisation as an increasing number of ‘traditional’ players 
have sourced knowledge from ‘non-traditional’ locations (Balachandra 2006; Haakonsson 
and Ujjual 2015; and Li and Yue 2005). While these new locations have recently 
experienced an advancement in its innovation capabilities with a large pool of talents and 
expertise (Athreye and Cantwell 2007; Lewin et al. 2009), the possibility to generate 
important knowledge still remains an open question for both researchers and practitioners 
(von Zedtwitz and Gassmann 2002; and Altenburg et al 2008). The narrative in this paper 
clearly shows that, although the consensus is that emerging economies generally present a 
unique and unknown operating environment in terms of political and legal context relating 
to innovation (such as strength of intellectual property right protection), in the most recent 
years, the role of these economies is changing drastically perceived by firms from 
advanced economies due to a number of changing factors, such as the increasingly 
internationalised standard of national education system and therefore the emergence of a 
large pool of skilled labour, a better legal framework, a converging national culture, and 
the widespread of foreign languages spoken (OECD 2008, 2014; UK Trade and 
Investment 2010). All of these developments provide latest support to the scholar view that 
creation of important knowledge is not the sole ‘privilege’ of the advanced economies but 
emerging markets knowledge-seeking has become the latest trend in global innovation 
strategy formulation (Haakonsson and Ujjual 2015; Hadengue et al 2015; and Haour and 
Jolly 2014).  
 
3. The ‘Transitioning’ China: From Production to Innovation  
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Although China has long been recognised as the ‘world factory’, in more recent years, the 
local environment witnessed a significant gradual shift towards greater focus on innovation 
(China Statistical Yearbook 2014; UNCTAD 2006, 2012). In fact, a large number of 
companies in China from different industries have begun mounting challenges in sectors 
which were traditionally preserved by American, European, Japanese, and South Korean 
businesses. For example, Beijing Genomics Institute, which is the world’s biggest genetic-
sequencing company, now claims to account for roughly 50 percent of global capacity and 
probably sequences more genetic material than Harvard University and the Massachusetts 
Institute of Technology combined. It also develops some of the world’s most advanced 
biologic-computing models (McKinsey Quarterly 2013]. In information and 
communication technology sector, Huawei developed its own innovative new smartphone 
platforms which are built on chips and software designed in-house. Its competitor Xiaomi, 
founded in 2010, is frequently compared to Apple for its marketing strategy. The sales of 
Xiaomi mobile phones were more than 15 million units in 2013 (Bloomberg Business 
2014). In the consumer electronics industry, Midea announced a highly efficient 1-hertz 
variable speed air conditioning compressor which was, surprisingly, ahead of foreign rivals. 
Finally, YY.Com, a voice-based communications and gaming service provider, has 
captured growing attention with its mass online karaoke, which is a highly popular activity 
locally (McKinsey Quarterly 2013). 
 A number of key factors have been identified to contribute to this seismic change. 
First of all, the changing business mentality among many local companies in China. For 
instance, John Oyler, CEO from a three-year-old Chinese biotech company BeiGene, 
underscored the attitude: “Anything is possible, we can make it happen. There is no 
challenge we cannot conquer, and we will surprise the world.” (McKinsey Quarterly 
2013). Second, the ever-closer collaboration between Chinese universities and companies. 
Chinese universities have gone through some significant changes. One of which is the 
huge interest in recruiting world class experts. When Fudan University in Shanghai 
planned to develop a waste water treatment science programme, it hired a world class 
academic from Singapore. Hence, as Chinese universities raise their games, they are 
becoming increasingly attractive innovation partners for companies. Many local and 
global firms have taken this opportunity, e.g., Intel has long collaborated with Chinese 
universities to sponsor research projects. Increasingly, these partnerships are seen as a 
means of outsourcing research and development. An extreme example is a local Chinese 
packaged-goods company which has conducted food science research almost entirely 
through a local university lab (McKinsey Quarterly 2013). Meanwhile, BeiGene’s 
spokesman describes Chinese universities as “underappreciated treasure troves of 
innovation pockets” (McKinsey Quarterly 2013). This finding is in line with Balachandra 
(2004)’s work who notes that the availability of a pool of skilled labour can be a crucially 
attractive factor to encourage Western firms to internationalise innovation activities. 
Apart from providing companies with top talents and research assistance, 
partnerships with universities can also benefit the companies in that these market players 
can gain access to any upcoming changes in policy direction and market rules, as Chinese 
professors often have close relationships with government officials and can pick up 
valuable information.  
 Third, the availability and utilisation of young generation of Chinese talents. A 
McKinsey’s spokesman noted his experience with young Chinese talents. For instance, 
Guosheng Qi is a 28 year old Tsinghua University graduate and the founder and CEO of 
Gridsum, a cloud-based web-analytics company. The company’s customers range from 
Baidu, which is the largest search engine in China, to multinational firms such as Coca-
Cola. Additionally, in 2012, it beat out companies from around the world to be titled one 
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of Microsoft’s most innovative new software partners. Another example is Lenovo’s 
intense recruitment of fresh talents straight from Chinese universities, which makes up 
roughly 70 percent of its company. This has enabled the company to sustain its 
innovativeness and a strong corporate culture (McKinsey Quarterly 2013).  
 Last, increasing government support for intellectual property protection and the 
transformation of China’s national innovation system. For intellectual property protection, 
the Chinese government has attempted to make it a core part of its innovation culture by 
being more supportive (Anderson et al 2009). For instance, the ministry of the Chinese 
government charged with prosecution of intellectual property violations announced the 
handling of 2,347 cases in 2012, which was up by 40 percent in comparison to the 
previous year (Orr and Roth 2013). Another example of active government support is the 
building of a 500,000 square metre facility next to Suzhou’s innovation park. The intention 
behind this move is to bring together intellectual property related agencies and leading 
technology companies to elevate important protection issues. In addition, it also improves 
the processing and quality of patent approval and protection. These examples reflect a 
growing appreciation of the importance of intellectual property protection in China.  
At the same time, the Chinese government has actively reformed the Soviet style 
innovation system since its inception in the 1950s. Prior to the 1980s, the Chinese system 
was characterised by the complete separation of science and technology activities in public 
research institutions from manufacturing in state-owned enterprises. The reform was then 
carried out to connect the two. In order to do so, the Chinese government pushed research 
institutions to adapt to the market environment and to conduct research that had industrial 
implications. The government took three specific steps between the 1980s and the 1990s in 
this regard (OECD 2008, 2009): 1) advocating the merger of some research and 
development institutions with companies in the 1980s; 2) offering financial incentives to 
commercialise research results through various programmes in the 1980s, including the 
well-known Torch Programme; and 3) transforming the established research centres into 
institutions with economic functions, such as production and consultancy organisations, 
from the 1990s. Meanwhile, MNEs and new technology firms have become more involved 
in the new national innovation system whereby more research has been conducted in China. 
Consequently, companies of various sizes have grown to become major contributors of 
national innovation system, where spending in research and development jumped from 
RMB 14 billion in 1995 to 44 billion in 2001. AZ PLC was at the forefront of these 
developments (Data Monitor 2005, Bernstein Research 2009, KPMG 2011).  
 
4. A Brief History of a Global Pharmaceutical Company: AZ PLC 
The very beginning of AZ can be traced back to 1913 when Astra was an independent 
company based in Sodertalje, Sweden. However, it was not until the 1930s that the 
company started its first set of research activities on a very small scale. The company since 
acquired a couple of factories in 1939 and 1942, making Astra the largest Swedish 
pharmaceutical company. Since its research and production extension, Astra established 
two product families and introduced them to the Swedish market in 1948. The profits from 
these families were then used to fund new drug development. To increase the chance of 
success, Astra relocated its Hassle research division to Gothenburg in 1954 in order to be 
near to Gothenburg University Medicine Faculty for collaborations. The collaborations 
were considered very successful as a number of blockbuster drugs were developed and 
sold (AstraZeneca: Our History, n.d.).  
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 Since the early 1990s, Astra witnessed increasing costs for developing new drugs 
and believed that the company needed a more international platform for the future. Hence, 
Astra started to eye for partners. It was not long before Zeneca became the ideal partner 
(The Independent 1998). Zeneca Group was formed by Imperial Chemicals Industries (ICI) 
in the 1990s to focus on the group’s pharmaceuticals business. The demerger of ICI later 
led to the merger of Astra and Zeneca in the late 1990s (The Independent 1999). This was 
considered as one of the largest-ever European mergers at the time and made them into the 
fourth largest pharmaceuticals company in the world. Tom McKillop, the new CEO for 
AstraZeneca noted:  
 
“Astra and Zeneca are a perfect fit in terms of highly complementary product portfolios as 
well as sales and marketing organisations. A similar management philosophy together 
with a strong science-based culture makes the companies natural partners.” 
(BBC News 1998) 
 
The merger clearly indicated the company’s intention to strengthen its innovation and 
world market share in the long run.  
The integration of the two companies’ worldwide organisational activities post-
merger called for some major structural changes and consequently, led to the formation of 
a new group arrangement whereby a much widened geographical scale was realised. 
Specifically, the USA, Canada, and Europe remain the three largest and more mature 
markets for the group whilst Asia Pacific (excluding Japan), Japan, Latin America, and the 
Middle East are seen as the younger markets with greater growth potential in the long run. 
Across these seven markets, three worldwide strategic innovation centres are established 
in Sweden, UK, and USA, responsible for the most advanced drug research for the global 
market. They are supported by four other important global innovation centres which are 
based in Poland, Russia, Japan, and most recently, in China. These centres are further 
complemented by clinical development at over forty sites around the world. Furthermore, 
the restructuring and expansion also involved the establishment of a number of 
manufacturing sites worldwide for the purpose of meeting regional and/or global needs. 
Sales and marketing divisions are also located near manufacturing sites to ensure rapid and 
responsive product supply (BBC News 1998). 
 
5. Epistemology and Methodology  
Turnheim and Geels (2013:1754) noted: “the ‘usefulness’ of history goes far beyond a 
dataset for the testing of hypotheses or history-friendly models. Instead, we suggest that 
historians practice a particular kind of explanation that has much to offer to innovation 
studies, particularly for understanding long-term change processes such as…” Our paper 
takes this stand to study the development (as a process) of innovation activities of an MNE 
in an EE.   
 From historian perspective, the understanding of social life is about ‘process 
tracing’ which “takes path dependence seriously and goes ‘inside the black box’ to explain 
how actions and changing contexts produce event chains.” (Turnheim and Geels 
2013:1754). In order to take into account of tracing the process, we echo the work of 
Turnheim and Geels (2013) by adopting the commonly used epistemological style by 
historians – ‘narrative explanation’.  It is suggested that such a style is strong in capturing 
complex social interactions through time and event sequences. Abbott (2001: 227) wrote: 
“theorising the social process via narrative is a deep tradition in both history and 
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sociology. If there is any one idea central to historical ways of thinking, it is that the order 
of things makes a difference, that reality occurs not as time-bounded snapshots within 
which ‘causes’ affect one another…., but as stories, cascades of events.” 
 In line with Turnheim and Geels (2013), the narrative explanation style which we 
follow in this paper is not about simply description of separate events but the trace of 
historical process. Our explanation is guided by previous literature and conceptual 
framework on the recently emerged pattern of internationalisation of innovation to non-
advance economies. This corresponds to the view of Gaddis (2002) that theories are likely 
to be embedded within narratives. On the other hand, “historians rarely perform formal 
tests of theories; instead, they judge theories and conceptual frameworks for their 
usefulness in writing plausible and interesting narratives.” (Turnheim and Geels 
2013:1755). Consequently, our paper also follows this approach in understanding the trend 
towards innovation in emerging economies through a longitudinal case study. The 
conceptual framework identified in recent literature in previous section will be confronted 
with the chosen case of AstraZeneca PLC in China between 1993 and 2014. Case study 
strategy is well fitted to exploratory research as it is rich in context, allows for real-life 
illustrations to explain an identified phenomenon (Eisenhardt and Graebner 2007), and 
enables ‘process tracing’ of series of events (Turnheim and Geels 2013: Yin 2003). The 
objective of our paper is not to tell a ‘full’ story but to provide an analytical narrative 
which follows the pattern of innovation internationalisation identified in recent literature.  
Within case study, researchers can choose to select either single or multiple cases. 
The decision to use either is largely dependent on its appropriateness in dealing with the 
topic (Yin 2003). While Yin (2003) suggests that multiple cases enable the logic of 
replication, in which the researcher replicates the procedures for each case and data from 
multiple cases concerning the same inquiry provides a basis for generalisation if patterns 
or differences are found. This study is not concerned with qualitative generalisation but in-
depth longitudinal exploration of the complexity behind innovation FDIs in emerging 
economies. Therefore, we are not concerned with producing results which can be 
generalised to other cases, industries, or the wider population in any way. Instead, we are 
simply interested to trace the process of innovation development in emerging economies. 
This means, any MNE which has established a strategic R&D centre in an emerging 
country is likely to be considered a ‘suitable’ case for the simple purpose of providing 
some initial explanation to the recent trend identified in literature and therefore plausibility 
of the conceptual framework. UNCTAD’s (2005) ranking of innovation FDIs shows China 
as one of the largest inward FDI destinations in terms of R&D activities. In comparison to 
its major competitors, AZ PLC has one of the longest operating histories in China and was 
one of the very first to set up a strategic R&D centre in the country (Bernstein Research 
2009). Hence, AstraZeneca in China is viewed as a suitable case for exploration.  
 
 
 
 
 
5.1 Data sources and collection methods 
With reference to Turnheim and Geels’ (2013) definition of secondary (journal articles 
and authored books) and primary (newspapers, government reports, and company annual 
reports) data, we draw on a wide variety of secondary and primary sources to highlight 
FDI activities AstraZeneca has undertaken during its operations in China. Although these 
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sources should be taken at face value, they provide interesting details for qualitative 
analysis which traces the gradual changes in the company’s operation. “This variety in 
data sources enables triangulation, and allows for a rich analysis…” (Turnheim and Geels 
2013:1755). A comprehensive list of data sources is provided in Table 1. 
 
 
 
Table 1. Primary and Secondary Data Sources 
Data (in alphabetical order) Source 
  
Books  China Medical and Pharmaceutical Industry 
Handbook  
 The Asia-Pacific Biotech Directory 
 International Directory of Company Histories 
 Foreign Companies in China Yearbook 
  
 
Company Annual Reports  AZ PLC 
 Zeneca Group PLC 
  
 
Corporate News Releases  AZ Global  
 AZ China  
  
 
Government Reports  China Food and Drug Administration 
 Ministry of Commerce, P.R.C. 
 China Statistical Yearbook  
 State Intellectual Property Office (China) 
  
 
Industry Reports  Bernstein Research 
 Bio Partnerships Asia 
 Chemical Market Reporter 
 KPMG Research 
 McKinsey Quarterly 
 Thomson Reuters  
  
 
Newspapers  Asia Pacific Biotech News 
 CBS News 
 China Daily 
 Jiangsu News 
 Wall Street Journal  
 The Financial Times 
 The Independent  
 The Telegraph  
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5.3 Data analysis 
The data analysis process was partially planned and partially emerged as the collection 
progressed. Appropriate adjustments were made throughout the study by way of 
examining emerging pattern from the raw data. Therefore, the process was fairly 
interactive. The longitudinal case is divided into three distinctive periodic phases using 
market-seeking, efficiency seeking, and knowledge-seeking definitions of FDIs identified 
in previous literature. For each period, the narrative traces the type of FDIs undertaken in 
China. We provide interpretations of the FDI activities undertaken in each period as well 
as over the course of the three periods in relation to the conceptual framework identified in 
previous literature. Specifically: 
 Phase 1: The first phase identifies the earliest forms of establishment of AZ in 
China when it first entered the country. This period covers from 1993 and 2001 where the 
entry modes, purpose of entry, and level of FDI are identified from data collected from 
newspapers, company website, and business publications. The definition of this period 
corresponds to market-seeking as the conceptual framework identified.       
 Phase 2: The second phase centres around the analysis of the subsequent 
development of AZ in China following phase 1 in terms of the changes in the level and 
nature of investments made in the country, the increasing variety of forms of establishment, 
and the new purposes of these changes. This stage of analysis covers the period of 2002-
2008 and is based on data collected from company sources, newspapers, and business 
publications. The definition of this second period corresponds to efficiency-seeking.  
 Phase 3: The final phase focuses on the most recent changes in the development of 
AZ China operations to date. Based on data collected from industry and company reports, 
newspapers, and business publications, this stage of analysis covers the period of 2009 to 
2014 where further key changes in its investments and forms of establishments were 
identified. The definition of this third period corresponds to knowledge-seeking.  
 Overall, the sum of these three phases makes up the whole developmental pattern 
of AZ in China. The next two sections provide a comprehensive analysis of the research 
context of China, and the background of the case company AZ PLC. 
 
6. AZ: The Three Phases of Innovation Internationalisation to China between 
1993 and 2014 
Based on the understanding of R&D internationalisation as analysed by Arvanitis and 
Hollenstein (2011), and Cantwell and Piscitello (2000), three distinctive phases of 
internationalisation of innovative activities of AZ in China are identified: 
 AZ China’s first establishment dates back to 1993 by Astra. Since then, the 
operation in the country has developed tremendously in terms of scale and scope. In 
particular, it is witnessed that the company is now heavily dependent on China operations 
for not only global production but increasingly more for strategic innovation. The three 
key phases of AZ operation in China are reviewed next. The first phase is between 1993 
and 2001when China’s first wave of fast economic growth took place. It was seen as a 
market with huge potential and therefore, gaining market share with existing products was 
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the top priority for the company – the North to South wave. This is identified in the 
literature as the ‘knowledge exploitation’ act, which AZ adopted to augment existing 
products to suit the needs of the Chinese patients. This type of subsidiaries is commonly 
recognised as the ‘local adaptation units’. Following its successful market expansion in 
China, during the second phase (between 2002 and 2008), AZ’s focus shifted towards 
strategic activities – innovation in China for China, which is the South to South wave. This 
move is commonly defined as local ‘knowledge exploration’ whereby new products are 
developed using available local knowledge for the local market. This type of activity is 
often pursued by ‘local R&D units’. During the most recent phase between 2009 and 2014, 
AZ’s further involvement in China has speeded up and is seen as the most significant to 
date, with serious efforts to developing global production and strategic innovation centres. 
This significant development in AZ’s China activities can be related to existing literature 
as ‘knowledge exploration for the global market’. This type of establishment is commonly 
recognised to be a ‘centre of excellence’ whereby new science is often discovered there 
and a key driver of worldwide product development. In other words, China becomes a 
crucial part of AZ’s global network and performance – the South to North wave (see 
Papanastassiou and Pearce 1999 for a comprehensive analysis of the types of overseas 
R&D laboratories).  
5.1 “Testing the water”: Initial expansion in China, 1993 – 2001 
The timing of Astra’s entry to China was carefully considered. As part of Astra’s global 
expansion strategy, the company already had an eye for the market for some time, and it 
was not till the early 1990s that the first step was taken. It was fuelled by a number of key 
economic changes in China. Since Xiaoping Deng’s introduction of the first economic 
reform in 1978, China has since set up five special economic zones where private firms 
are allowed between 1980 and 1994, and opened up fourteen coastal cities for foreign 
investments in 1984, and many more examples in the 1990s. As part of continuous 
economic reforms, China started mass privatisation in the following decade to move 
towards a more market-based system. This shift drastically accelerated the economic 
expansion and was the deciding point for Astra to establish its first sales and marketing 
subsidiary in the country. Subsequently, in 1993, Astra took the first step to set up Astra 
(Wuxi) Pharmaceuticals Co. Ltd in Jiangsu Province, not far from Shanghai ( Pederson 
2008; World Scientific 2003).  
Jiangsu is an ideal location for Astra for a number of reasons. For one, in 1992, 
many parts of Jiangsu Province were made into economic zones and Wuxi city established 
Wuxi New District – one of the largest industrial parks in China. The new district was 
known for providing strong support for international operations. For two, Jiangsu is 
ideally located next to trade intensive regions such as Zhejiang and is home to hundreds of 
thousands of businesses. For three, to attract foreign investments, national and local 
governments offered attractive incentives. Hence, the overall business environment of 
Wuxi at the time of Astra’s entry was one of the most ideal places in China. This also 
worked in favour of Astra as its strategy at the time was to maintain full control rather than 
joint-ventures from the start with a view for the long run despite its lack of local 
knowledge and experience (AstraZeneca Corporate News Releases, n.d.; Invest in Jiangsu 
2006). 
In the following year of Astra’s China set-up, Zeneca also entered China but in the 
form of a joint-venture with Sinopharm, which is a state-owned corporation. Sinopharm, 
also known as China National Pharmaceutical Group Corporation, was the largest 
pharmaceutical and healthcare group in China, with a very well established network in the 
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country. It owned 22 subsidiaries and holding companies including research, distribution, 
and production facilities. The initial agreement between Sinopharm and Zeneca was for 
the sole distribution of Zeneca’s blockbuster drugs at the time (Zeneca Group PLC Annual 
Report 1994). Similar to Astra, this move was also an indication of Zeneca’s attempt to 
move into the Chinese market early as part of their global expansion of existing products. 
Following one year into the agreement, Zeneca felt the huge potential of the market and 
invested further to established sales and marketing operations in 1995. Benefiting from the 
rapid economic growth in China in the following few years, Astra and Zeneca both had 
successfully positioned themselves in the Chinese market to be leaders in the sale of 
specific drugs. They also established offices in over 20 major cities. However, the joint 
venture demerged for Zeneca around the same time when Astra and Zeneca merged. 
Following the merger the new AZ embarked on the most exciting Chinese venture 
at the time, i.e. an accumulative investment amount of $270million (in comparison to $121 
million by GlaxoSmithKline around the same time) in building its first world class 
production facility in Wuxi New District where Astra’s previous Chinese operations were 
initiated (Chemical Market Reporter 2001). The investment decision came through as both 
Astra and Zeneca were performing well in China. AZ CEO Tom McKippop commented in 
an interview: “There are over a billion people in China. It is potentially a very large 
market. I believe the prospects for new medicines coming into China are very good”. The 
project started in early 1999 and by the end of April, 2001, it was completed and opened 
for operation. The new production plant employed 600 workers and produced 95% of all 
AZ’s products sold in the country. According to an AZ official: “There are Western 
manufacturers with plants there [in China], but this is one of the largest investments made 
by a pharmaceutical company.” (Wall Street Journal 2001; AstraZeneca Annual Report 
2001). 
During this phase of AZ’s expansion in China which can be partly characterised by 
strategic focus on market expansion, AZ also made their first important step in investing in 
research in the country – the first step in North to South development. Between 1996 and 
2001, AZ undertook nine international multicentre clinical trials in the respiratory field in 
China with the involvement of over one hundred and thirty domestic hospitals and 
institutions. By 2001, AZ invested $35 million in clinical trials and conducted thirty seven 
clinical research projects involving approximately twenty thousand patients in more than 
one thousand domestic medical sites (Asia Pacific Biotech News 2001; AstraZeneca 
Annual Report 2001). The objectives of these investments were to develop drugs that are 
specific for the Chinese patients with specific diseases. To further AZ’s effort in local 
innovation, its emphasis on the importance of strategic partnerships with Chinese research 
institutions became evident. For instance, the company and Shanghai Jiaotong University 
launched a joint research project on genetic links to neuropsychiatric diseases 
(AstraZeneca Corporate News Releases, n.d.; China Daily 2001).  
Although AZ research related investments during this period were not for building 
own innovation facilities, the company was still one of the first foreign companies to 
commit to local research at the time. This move was further encouraged by China’s entry 
into the World Trade Organisation in late 2001. This was crucial for the company’s 
business strategy in China as it meant more protection over intellectual property rights and 
curtailing of counterfeit pharmaceuticals. Hence, this phase of the development process 
signals a heavy strategic overall emphasis on market-seeking with some elements of 
efficiency- and knowledge-seeking at the stage of embryo.  
5.2 “Resting assured”: Second phase of expansion in China, 2002 – 2008 
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The booming of the Chinese market came into force in 2002 as the country officially 
became a member of WTO, which further fuelled the already rapid developing economy. 
Being one of the early movers and building on its existing research-intended investments 
in the previous years, AZ continued its innovation investment in China on an ever greater 
scale (Ministry of Commerce, P.R.C. 2005; AstraZeneca Annual Report 2008). Two major 
categories of developments took place: extensive local partnering and the establishment of 
own research institutions, despite the fact that this was still the period when China was 
viewed by most foreign investors as a more attractive destination for production and sales. 
These are strong indicators of the South to South developmental wave.  
In terms of the former category of developments, for instance, in 2003, AZ took a 
major step in forming the most significant partnership at the time with Peking University’s 
Guanghua School of Management to fund the China Centre for Pharmacoeconomics and 
Outcomes Research. It was one in a series of research and educational programmes aimed 
at supporting reform of the country’s healthcare system. During the first three years of the 
partnership, AZ provided over $360,000 in sponsorship to help set up and establish its 
research, advisory and training programmes for government officials, hospital executives 
and pharmacy directors. In particular, the sponsorship helped fund a series of research 
seminars hosted by international experts, and sponsor of two-year fellowship programmes 
for trainees, hosted alternatively by the School and AZ, and facilitate short-term training 
programmes across the country (AstraZeneca Corporate News Releases, n.d.).  
Continuing its innovation investment tradition in China, in 2007, AZ took another 
major step in its local development by forming a strategic partnership with Peking 
University Third Hospital to set up the company’s first Clinical Pharmacology Unit in the 
country (AstraZeneca Corporate News Releases, n.d.; China Daily 2007). In the same 
month, AZ and Guangdong Province People’s Hospital jointly established a research 
laboratory with the focus on translational science. The Unit was intended to augment 
existing clinical research capabilities and undertake Phase I clinical research including 
clinical pharmacology and safety evaluations – steps necessary for launching new 
medicines in China. This move fastened the launch and patient access to new medicines in 
China. As part of the partnership agreement, AZ offered personnel training, system audits, 
and consulting services. It also invested in the hospital’s facility enhancement as required 
for carrying out clinical research of medicines for infections, diabetes, and cardiovascular 
diseases. Furthermore, it was set to expand the capabilities of early phase clinical research 
for local clinical pharmacology organisations, and take China’s clinical research 
capabilities to a new level through further research cooperation and academic exchange 
with the local medical community (AstraZeneca Annual Report 2007; Ministry of 
Commerce, P.R.C. 2007).  
In 2008, AZ reached further to the Shanghai Institute of Materia Medica to 
establish the Drug Safety Evaluation Joint Research Centre in Shanghai Pudong Science 
Park of Chinese Academy of Science. This was also intended to fasten speed to market 
progress in the country. In the same year, as the agreement between AZ and Pharmatech 
Wuxi came to an end with the success of achieving targets two months ahead of schedule, 
AZ decided to extend its contract with the company to continue to synthesise compounds 
according to AZ’s designs in the new arrangement in order to further expand the 
company’s global compound collection. Deborah Hartman, AZ vice president, noted: 
“Wuxi had exceeded expectations in the first agreement, delivering value…beyond the cost 
savings in labour and materials.” (Jiangsu News 2008). 
In addition to these major partnerships, AZ also expanded its clinical research 
capabilities by increasing the number of scientific collaborations with local Chinese 
pharmaceuticals firms. For example, it signed a two-year partnership deal worth $14 
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million with Wuxi PharmaTech for compound collection synthesis. In the same year, AZ 
also entered into a license agreement with Cubist Pharmaceuticals, Inc. for the 
development and commercialisation of Cubicin (i.e., daptomycin for injection) in China 
(AstraZeneca Corporate News Releases, n.d.; Bio Partnerships Asia 2011).  
For the latter category of development, AZ made a number of historical records. 
For example, in 2002, AZ was the first of its kind to launch a localised Clinical Research 
Unit for East Asia region in Shanghai. The significant number of high quality medical 
talent available in the city was the reason for the location decision. The Unit aim was to 
oversee East Asia clinical research in mainland China, Hong Kong, Taiwan, and Korea, 
and the clinical research was conducted by more than forty high-calibre Chinese 
researchers (Pharma Times 2006). This signified that the country would become a critical 
component of AZ’s future global trials and can significantly reduce the time it takes for 
drugs to be made available to Chinese patients (AstraZeneca Annual Report 2002; 
Ministry of Commerce, P.R.C. 2005).  
Another important development was in 2006 when AZ invested more than $70 
million in the establishment of the Innovation Centre China, which again was the first of 
its kind in the country (Ministry of Commerce, P.R.C. 2006; AstraZeneca Annual Report 
2006; China Pharmaceutical Industry Investment Promotion Report 2014). It was also one 
of the most advanced scientific research centres of the Group outside of the UK, Sweden, 
and USA. It evidenced the company’s dedication to research in China and the ambition of 
having a strong innovation presence in the region. Jan Lunberg, executive vice-president 
of Discovery at AZ PLC, commented: “It will be an integral part of our global innovation 
activity aimed to ensuring that the right patients are treated with our oncology drugs and 
will take advantage of the excellent science base in Shanghai where there is a burgeoning 
biotech industry.” Balachandra (2004) emphasises that filling gaps in the capabilities of 
the innovation function is a key consideration for firms to internationalise innovations. 
Although the beginning of AZ China did not seem to suggest so, the formation of this 
innovation centre shows its major role in contributing to AZ’s global knowledge base. 
Other examples include the creation of an in-house business school, known as AZ 
China Business Institute, for employee development and patient education programme in 
2005. In the following year, AZ Academy for Chinese healthcare professionals for 
medical education and clinical research was opened. It was intended to educate and update 
current and future generations in the latest advances in scientific and medical knowledge 
(AstraZeneca Corporate News Releases, n.d.).  
 Apart from innovation investments, in 2006, AZ announced its commitment to an 
additional $35 million investment over the next five years to increase its productivity of 
the Wuxi site. The site also passed both the China and European Union Good 
Manufacturing Practice certification and was since authorised to export products to 
European Union and other countries adopting the same standards. Moreover, AZ’s China 
sourcing centre was founded in Shanghai in the same year as part of the company’s effort 
to strengthen its global sourcing of active pharmaceutical ingredients. These developments 
further signalled AZ China’s increasingly evident global role. 
 In summary, by 2009, AZ employed more than two thousand and nine hundred 
staff locally, had a network of more than twenty marketing and sales offices, a world class 
manufacturing site in Wuxi, clinical research facilities, and multiple collaborations and 
partnerships with local academic and medical institutions. At the same time, AZ enjoyed 
sustained business growth with continuous sales increase over the years as it was ranked 
number one in terms of sales volume of prescription medicines among foreign 
multinational in China (eleven of its branded products held a Number One position in 
market share). Much of this is to do with China’s rapid economic growth and increasing 
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demand for better healthcare.). Such an innovation internationalisation motive was found 
in the literature of Pearce et al (1992) and Balachandra (2004), who suggest that MNEs 
internationalised their innovation activities to other locations where growth opportunities 
are apparent. Particularly, major FDIs during this phase reflect a heavy emphasis on not 
only market- but much more towards efficiency-seeking.   
5.3 “Feeling settled”: Third phase of expansion in China, 2009 – 2014 
To further its Southern expansion, on 9thSeptember 2009, AZ held the ground-breaking 
ceremony in Shanghai Zhangjiang Hi-Tech Park (which was known as China’s medicine 
valley) for its new China site, which included AZ’s new China corporate headquarters for 
China and Asia Pacific, marketing operations, Innovation China Centre, and Academic 
training and regional functions. It became one of the only three corporate headquarters of 
AZ PLC besides USA and UK (AstraZeneca Corporate New Releases, n.d.; AstraZeneca 
Annual Report 2009; China Pharmaceutical Industry Investment Promotion Report 2014). 
A solid foundation was finally laid for AZ China for the long run. By the end of this 
financial year, AZ’s accumulated sales were more than $800 million (The Telegraph 2010). 
On the other hand, it was also an important period for AZ as many rivals started to seek 
big breakthroughs into the market. For the first time, AZ’s leadership position in China 
was replaced by the merger of Pfizer and Wyeth in October 2009. To reclaim this spot, AZ 
had its plans. David Brennan, Chief Executive Officer of AZ, believed that, with a 
population of 1.3 billion in China, a burgeoning middle class and increasing prevalence of 
Western-style diseases, the Chinese market would offer the most opportunity for growth, 
and product offerings were the way to regain its position (The Telegraph 2010, Thomson 
Reuters 2010). This was for a number of reasons: one, when the right drugs became 
available, they could make into China’s National Reimbursement Drugs List which 
allowed patients to claim a fifty percent rebate. Two, China was always considered a 
marketplace where mature drugs could still generate sales long after patent expiration, 
which was different from the situation in the West. Three, the traditional practice in China 
for drug selection is that once particular branded drugs were accepted by the doctors and 
patients, there was a strong tendency to stick to it permanently though the initial 
acceptance tended to take a little longer (AstraZeneca Annual Report 2010; China Food 
and Drug Administration, n.d.).  
Hence, in order to widen and better its product offering as the core source of 
sustainable competitive advantage, AZ continued its aggressive innovation localisation in a 
number of ways. First, it is AZ’s internal innovation capability building in China. 
Specifically, by 2011, the Innovation China Centre had already built strong capabilities in 
translation sciences for oncology research for the Chinese market since its opening over 
four years ago. Hence, the Centre embraced a new mission, which was to deliver candidate 
drugs and ultimate Proof of Concepts and valuable drugs to address the significant unmet 
medical needs of patients in China. This new mission, dedicated by the Swedish research 
headquarters, signalled a new level for the China centre. The mission required the Chinese 
research team to focus on the discovery and development of new drugs specifically 
targeting diseases that were more prevalent. This included working closely with AZ 
Innovative Medicines Unit to exploit potential drugs to treat liver and gastric cancer and 
other cancer with high prevalence in China (McKinsey Quarterly 2012). 
Second, and more importantly, a strong focus towards more extensive and 
deepened advance-research collaborations locally. According to Dr Ajay Gautam, AZ’s 
Executive Director for China and Emerging Markets External Collaborations: “AZ is 
increasingly focusing on early stage academic collaborations with institutions because we 
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believe that working with partners across the globe who have fresh, innovative ideas and 
approaches will help us accelerate the discovery of new medical breakthroughs.” A list of 
the major collaborations during this period is provided in Table 2. 
 
 
Table 2 List of Collaborations (between 2010 and 2014) 
Year 
 
Means of Innovation 
Activity 
 
Purpose of Innovation Activity Target Market 
2010 Partnership agreement with 
Peking University 
Discovery and development of 
new treatment for diabetes, 
obesity, and atherosclerosis 
Chinese and 
global patients 
2010 Partnership agreement with 
No. 1 Affiliated Hospital of 
Guangzhou Medical 
College 
Basic research on chronic 
obstructive pulmonary disease 
Chinese patients 
2010 Research collaboration with 
BioDuro Clinical Research 
Discovery research in respiratory 
and inflammatory diseases 
Chinese and 
global patients 
2012 Partnership agreement with 
WuXiAppTec, and with 
technical and development 
support from AZ biotech 
subsidiary Medlmmune in 
U.S. 
Development and 
commercialisation of a novel 
biologic for autoimmune and 
inflammatory diseases 
Chinese patients 
2012 Research collaboration with 
Ironwood Pharmaceuticals, 
Inc 
Development and 
commercialisation of linaclotide 
for irritable bowel syndrome with 
constipation and chronic 
idiopathic constipation 
Chinese and 
Global patients 
2014 Research collaboration with 
Shenzhen University Health 
Science Centre 
Pre-clinical research on chronic 
kidney disease 
Chinese patients 
2014 AZ China Innovation 
Centre 
Discovery of first AZ pre-clinical 
candidate drug for oncology 
Chinese patients 
2014 AZ Global Medicines 
Development Unit 
collaborates with China 
Innovation Centre 
Creation of an innovative local 
portfolio to support local growth 
Chinese patients 
(Source: www.astrazeneca.com/partnering; China Food and Drug Administration) 
 
 
Apart from using local collaborations as a way to improve product offerings, AZ 
also brought in external capabilities that complemented the core internal expertise already 
available at the China centre in order to bring innovative new drugs to the market faster. 
One of the examples was an acquisition agreement with a privately-owned generics 
manufacturing company - BeiKang Pharmaceutical Company Ltd - from Conghua City, 
Guangdong Province, in 2011 (Chain Drug Review 2012). The deal gave AZ access to a 
portfolio of injectable drugs used to treat infections which the company aimed to make 
them available to Chinese patients. This move reinforced the company’s commitment to 
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bringing original and high quality branded generic drugs to the ‘broader’ market to 
increase the accessibility and affordability for patients who were previously underserved. 
Mark Mallon, President of AZ China-Pacific region, commented: “Our new acquisition 
further underscores our intention to serve the health needs of Chinese patients through our 
innovative medicines and, increasingly, high quality branded generic treatments that are 
locally produced to global standards.” .  
Apart from improving product offerings for the Chinese market, AZ China also 
entered into a number of research collaborations for the purpose of developing drugs 
which were required not only by local patients but also for the global market. This move 
signalled AZ China’s first move towards becoming a global contributor of innovation – the 
start of the South to North wave.  
For instance, in 2011, AZ and Chi-Med China co-developed and commercialised a 
novel cancer therapy called Volitinib. Christian Hogg, Chief Executive Officer of Chi-Med 
noted: “We are very much looking forward to collaborating with AstraZeneca around 
Volitinib. Our collaboration will support the development and commercialisation of this 
novel oncology innovation, discovered in China, to the global market on an accelerated 
basis...” (AstraZeneca Corporate News Releases 2011; Thomson Reuters 2011). In 2014, 
AZ China and Tianjin Medical University signed cardiovascular research collaboration. 
The partner university was one of the leading medical and scientific institutions in the 
country, making it an ideal partner for AZ. The agreement was to focus on exploring novel 
targets against cardiac fibrosis. This was considered a long-term collaboration as no 
therapy for such a disease was available globally due to lack of knowledge about its 
underlying causes.  
 In support of the research expansion activities, in 2011, AZ made two strategic 
investments in expanding its manufacturing operations in China.  One of these was a 
group record investment of $230 million for setting up a world class manufacturing 
facility in China Medical City - Taizhou, Jiangsu province (AstraZeneca Annual Report 
2011; Ministry of Commerce, P.R.C. 2011). The new plant enabled the company to meet 
the growing demand for its products in China while expanding availability to patients in 
the urban and rural communities who traditionally had limited access to established drugs. 
The underserved market was estimated to be more than 900 million people. It also allowed 
AZ to free up some capacity at the existing plant in Wuxi to bring on more new innovative 
products that were to be launched in the coming years. The second investment was to 
construct a new injection solution plant as part of an extension to Wuxi site for producing 
over 30 million advanced drugs per year and a new hub for receiving and packaging drugs 
for the China Pacific region, including Thailand, Philippines, and Australia, as demand 
from these areas were growing. Sheena Behn, manager of Wuxi site, commented: “You 
want a hub in the region because you want to be close to the countries you are serving. 
Geographically Shanghai port is the biggest in the world so you can move stuff around 
pretty easily.” Further to the new hub, AZ also moved its production of active 
pharmaceutical ingredients from the UK to China as the standard of the Chinese site 
became world class (CBS News 2009). By end of year 2014, AZ has recorded over 1,500 
patents with State Intellectual Property Office in China (SIPO, 2015). This third phase 
shows the greatest emphasis on knowledge-seeking alongside market- and efficiency-
seeking objectives. This is in line with previous literature.  
 In summary of the three phases analysed above, Figure 1 below illustrates all key 
FDIs AZ has made between 1993 and 2014, where phase one can be characterised as 
mainly market and production oriented, phase two as partially the same to phase one and 
partially focuses on localised innovations, and phase three as mainly local to global 
innovation.  
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Figure 1. The Investment Pattern of AZ China between 1993 and 2014 
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7. Discussion: A Theoretical Interpretation of AZ Internationalisation of 
Innovation in China 
6.1 The Three Distinctive Phases in China 
In light of AZ China’s operations over three subsequently distinctive phases, this section 
provides a theoretical discussion of the identified evolutionary process.  
 Phase One: The historical analysis of the initial stage of AZ’s establishment in 
China reveals that the growing market size for expansion potential and the abundant 
availability of cheap labour for low-cost production offshoring were the initial reasons 
which led to AZ’s first entry to the country. This is very much in line with the many 
established views on firms’ motivations for FDIs in less developed economies (Dunning 
1993, Johanson and Vahlne 1977). In comparison, the traditional theoretical view of 
innovation is that it never happens in the ‘South’ For instance, Porter (1989) and Vernon 
(1965) both argue for innovation at home or ‘nearby’ locations in order to maintain control 
and knowledge advantages. However, the later stage of Phase One shows a few different 
internationalisation activities undertaken by AZ which can be defined as R&D related 
adaptation and localisation. This can be argued to signal AZ’s first ever investment made 
in a low-cost country for the purpose of any kind of innovation activities. In this case, the 
‘South’, for the first time, has become a destination not only for market expansion and 
production offshoring but for R&D related activities though of low level. This in a way 
challenges the traditional view of Vernon (1965) and Porter (1989). The empirical finding 
is coherent with the view of Pearce (1999), Pearce and Papanastassiou (1997) and others. 
For example, Florida (1997) suggests that the non-innovation activities in a foreign 
location are the main reason behind internationalising some R&D activities. He argues that 
as production became internationalised, technical support and backup were required to be 
on-site in order to ensure timely problem-solving, hence, some internationalisation of 
innovation becomes mandatory. By the end of Phase One, an evolutionary process of AZ’s 
internationalisation activities in an emerging economy starts to emerge, i.e., the ‘North to 
South’ wave of internationalisation of innovation (innovations from advanced economies 
to be adapted for the Chinese market). 
 Phase Two: The subsequent analysis of AZ’s China operations during the second 
period reveals some further developments in terms of its innovation activities. While the 
firm continued to invest in non-innovation activities such as marketing, sales, distribution, 
and production in the country to increase growth and profits, which are very much in line 
with well-established theories including Casson (1992) and Buckley (2014), its 
investments in R&D activities in the country have increased more significantly in terms of 
intensity. This is strongly reflected in the changes of the types of innovations from the 
identified low-level adaptation in Phase One to more advanced testing and discovery of 
drugs for the local market as identified in Phase Two. For the very first time, advanced 
R&D is carried out in an emerging economy despite AZ’s global presence in terms of 
knowledge sourcing. This newly identified development signals another important 
evolutionary step along the continuum of AZ China’s internationalisation of innovations 
pattern: the ‘North to South’ wave (as per Phase One) is drifting towards the ‘South to 
South’ wave (Chinese innovation for the Chinese market). This finding corresponds to the 
works of Contractor et al. (2010), D'Agostino et al. (2013), and UNCTAD (2005).  
This finding can be explained by Pearce et al (1992)’s work that MNEs 
internationalise innovation units on the basis of absence of local innovation competitors, as 
such a move allows firms to derive distinctive new product lines. This enables the firm to 
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initiate and focus on extending and deepening their innovation activities targeted at the 
local market. Thus, overseas innovation units are able to bring in local knowledge and 
design to satisfy the local niche market, which in turn creates further market development 
opportunities. This is especially beneficial for MNEs in large and growing markets where 
innovation units can help retaining a secure market share. This is confirmed in the case of 
AZ China where localised innovation has enabled the firm to be close to Chinese patients 
to understand the most prominent disease, conduct trials, and produce effective drugs. 
However, these works were developed in the traditional context of the ‘North’. Therefore, 
the conventional wisdom regarding destinations for innovation FDIs, as supported by 
Arvanitis and Hollenstein (2011), Cantwell and Piscitello (2000), and Pearce and 
Papanastassiou (1997), is largely challenged for the first time in this study.  
  Phase Three: The analysis of Phase Three data indicates the most alarming 
development of AZ China to date. The findings suggest that apart from further 
investments to enlarge markets, production, and sales in China and Asia (where corporate 
Asian regional headquarters is established in China), AZ continued to deepen its 
involvement with local partners and in its own research centres for the advance research 
and discovery of breakthrough drugs for dealing with local diseases. The firm also 
intensifies its ‘South to South’ commitment by innovating not only for China but also for 
the Asian region. This finding continues to challenge the traditional view of 
internationalisation of innovation. Never-the-less, in Phase Three, the most significant 
development of the company in the country is the undertaking of world-leading R&D for 
the purpose of addressing knowledge gaps in drug discovery for some of the world’s most 
complex and challenging diseases. The ‘spell’ is finally broken whereby the ‘South’ is no 
longer seen as solely in the receiving end of valuable knowledge transfer but a world class 
provider of strategic knowledge which can potentially determine an advance-economy 
firm’s success for years to come. This finding is arguably one of the greatest criticisms of 
the long-established view on internationalisation of innovation (Arvanitis and Hollenstein 
2011, Cantwell and Piscitello 2000, Contractor et al. 2010, D ‘Agostino et al. 2013, and 
Pearce and Papanastassiou (1997), as none of these studies have addressed the full extent 
to which innovation focused FDIs have evolved in an emerging economy as presented in 
this paper. It is evident that almost no research (to date) has empirically answered a similar 
call to this paper; hence, the significance of the findings from these three phases should be 
undervalued or taken lightly or down played.  
6.2 The evolutionary pattern across the ‘North’ and ‘South’  
The theoretical discussions of the three specific phases evidence a progressive 
evolutionary pattern of AZ’s innovation in China, from the early stage of ‘North to South’ 
focus, to ‘South to South’, and now ‘South to North’. For the reasons behind the evolution 
in overseas innovation, Penner-Hahn (1998) and Ito and Wakasugi (2007) take the 
organizational learning perspective, derived from the evolutionary theory of Kogut (1988) 
and Kogut& Zander (1993), and suggests that firms initially tend to undertake low level 
investment in innovation activities until they learn enough to invest extensively in their 
foreign innovation activities. This is because sequential internationalisation process allows 
MNEs to learn about its new environment where they are able to obtain understanding of 
the nature of the research process and the national context in which the innovation takes 
place (Michell, Shaver, and Yeung 1994). Stopford and Wells (1972)’s earlier work, while 
not based on organizational learning paradigm, also suggest the gradual process of 
undertaking more intensive innovation activities as the MNE gains substantial knowledge 
of the local environment. This is exactly the case in the evolutionary process of AZ China 
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as the firm learnt about the market by first entering with sales and marketing and later 
production. When experience and knowledge provided confidence and reduced chances of 
failure, AZ China started to invest more in innovation. This conclusion is supported by the 
work of Li and Yue (2005) who identify that innovation in China goes through four types 
of stages from concentrated to dispersed research and development activities. Similarly, 
the empirical evidence from Sapelak and Ricalde (2008)’s work suggests that firms go 
through four patterns of R&D internationalisation, from internationalisation of basic R&D 
to advanced R&D. Hence, building on the case study of AZ China and in supporting of 
findings of UNCTAD (2005), Figure 2 below conceptualises the full extent to which AZ 
innovation has evolved in China during the period of 1993 – 2014 where a new pattern of 
internationalisation of innovation is suggested.  
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Figure 2. An Evolutionary Process for the Internationalisation of Innovation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
8. Conclusions  
The case of AZ’s historical development with specific reference to the growth of 
innovation capability in China over two decades has revealed a new pattern of 
internationalisation. Although it may be argued that the internationalisation of innovation 
by MNEs to emerging economies, as indicated in the case of AZ China, is uncommon and 
too complex to be explained by existing theories which were developed in a different 
context, an assessment of this new phenomenon is needed to establish where the current 
theoretical paradigm is lacking in interpreting the new phenomenon. This paper challenges 
the traditional view (“North to North wave”) by suggesting a number of incremental waves 
including “North to South”, “South to South”, and “South to North”. The detailed case of 
AZ China has evidenced these new waves and highlighted how an emerging country can 
become an ideal location for innovation. It indicates that emerging economies are no 
longer the destinations for only market and cheap labour but have become increasingly 
important players in global innovation.  
 This paper makes a number of important and timely contributions. First, it is one of 
the first to challenge the conventional wisdom and investigate the possibility of emerging 
economies in offering innovation for the global market. Second, some of the existing 
theories which are built upon the traditional context are discussed in relation to the 
emerging economy context whereby support for an evolutionary process is found. Third, 
the most important contribution this paper makes is the conceptualisation of the four waves 
of internationalisation of innovation which began with ‘North to North’ (wave 1) and 
‘North to South’ (wave 2) as the more accepted developments in existing literature, and 
gradually shifted towards ‘South to South’ (wave 3) and ‘South to North’ (wave 4), with 
the fourth one being the most recent and unconventional development of all.  
Home (Advanced Country) 
Away (Emerging Country) 
Time 
 
   
Experiential 
Knowledge 
Overseas 
North-North 
North-South 
South-South 
South-North 
‘North’ represents ‘advanced economies’ 
‘South’ represents ‘emerging economies’ 
             represents ‘distance from home country’ 
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 Practically, the success of AZ China highlights the importance of time and 
experiential knowledge in understanding and deepening involvement in the local market. It 
also reveals the increasingly significant contributions emerging economies can make to the 
strategies and future competitiveness of knowledge-intensive companies. Whilst policy 
related weaknesses are still apparent, governmental support and availability of expertise 
and a fast-growing market are important considerations for locating R&D activities in the 
‘unconventional’ regions.  
 There are some common limitations associated with case study. A single 
longitudinal case reflects the development of the chosen sample per se and therefore 
should always be very carefully considered in relation to others. It is likely that a second 
case may reveal a different picture to the narrative we provide in our paper, however, our 
initial objective was not to provide generalizable outcomes but to provide a contextually 
rich analysis of a particular case in light of the recent literature and emerged conceptual 
framework. Moreover, AZ’s evolution is largely a response to the market maturation of the 
host country which can be viewed as a demand side challenge. To further our 
understanding of this important topic, it will be of great value if future research can be 
conducted to explore some of the key success factors to the internationalisation of 
innovation to and from the ‘South’. It will also be insightful to investigate the implications 
of ‘South to North’ wave on MNEs, institutions, and countries, as this challenges 
everything we currently know about the internationalisation of innovation. Next, it would 
be interesting to see if AZ’s evolutional model in China has been followed by other MNEs 
in China or other emerging markets. While we claim AZ’s innovation strategy in China as 
part of its growth strategy in a host country is not an oddity or outlier, will other MNEs 
take this following the leader approach and adopt something similar in their engagement 
with the emerging markets? Lastly, while our earlier discussion acknowledges the different 
types of R&D units within the evolutionary process, we recommend further studies to 
formally assess the links in a systematic way to extend our knowledge on this important 
but complex phenomenon.  
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